The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Shanu Modi, William Jacot, Toshinari Yamashita et al. · New England Journal of Medicine · 2022 · 2.3K citations · Full text

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Shanu Modi, Cristina Saura, Toshinari Yamashita et al. · New England Journal of Medicine · 2019 · 1.9K citations · Full text

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

Antonio C. Wolff, M. Elizabeth Hammond, Kimberly H. Allison et al. · Archives of Pathology & Laboratory Medicine · 2018 · 1.4K citations · Full text

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

Leticia De Mattos‐Arruda, Regina Mayor, Charlotte K.Y. Ng et al. · Nature Communications · 2015 · 822 citations · Full text

Plasma Ctdna, Pathology, High-grade Gliomas +19

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Sara A. Hurvitz, Roberto Hegg, Wei‐Pang Chung et al. · The Lancet · 2022 · 580 citations · Full text

Breast Oncology, Medicine, Clinical Trials +8